Performance
Stock factor profile
DIVI'S LAB.
DIVISLAB · Healthcare · Pharmaceuticals & Biotechnology
Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 16,543 full-time employees. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).
DIVI'S LAB. reported revenue of ₹3,676 crore for Sep 2026, up 35.4% from a year earlier. Net profit was ₹1,127 crore (up 63.6% year on year). Return on equity was 15.3% in Mar 2026. Promoter holding was 51.88% in Sep 2026, down 0.01 points over 8 quarters.
Equity review factors
Factor profile
Factor scores are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags and screen results for DIVI'S LAB. are part of the Wright portfolio review.
Run your free portfolio reviewFundamental snapshot
Fundamentals at a glance
Reported results
Quarterly (₹ crore)
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3676 | 3080 | 2831 | 2604 | 2715 | 2410 | 2585 | 2319 |
| Net profit | 1127 | 902 | 751 | 583 | 689 | 545 | 662 | 589 |
| Net margin % | 30.7 | 29.3 | 26.5 | 22.4 | 25.4 | 22.6 | 25.6 | 25.4 |
| EPS (₹) | 42.45 | 33.98 | 28.29 | 21.96 | 25.95 | 20.53 | 24.94 | 22.19 |
Reported results
Annual (₹ crore)
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10560 | 9360 | 7845 | 7768 | 8960 | 6969 | 5394 | 4946 |
| Net profit | 2568 | 2191 | 1600 | 1823 | 2960 | 1984 | 1377 | 1353 |
| Net margin % | 24.3 | 23.4 | 20.4 | 23.5 | 33.0 | 28.5 | 25.5 | 27.3 |
| EPS (₹) | 96.73 | 82.53 | 60.27 | 68.69 | 111.52 | 74.75 | 51.85 | 50.96 |
Ratios · Mar 2026
Returns, leverage and growth
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| ROE % | 15.3 | 14.6 | 11.8 | 14.3 |
| EBITDA margin % | 35.0 | 34.2 | 31.1 | 33.4 |
| Net margin % | 23.2 | 22.6 | 19.6 | 22.5 |
Ownership
Shareholding pattern (%)
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51.89 | 51.89 | 51.89 | 51.89 | 51.88 | 51.88 | 51.88 | 51.88 | -0.01 |
| FII | 17.99 | 18.01 | 19.74 | 19.39 | 20.08 | 20.29 | 20.2 | 20.38 | 2.39 |
| DII | 20.54 | 20.71 | 19.05 | 19.76 | 19.28 | 19.22 | 19.38 | 19.17 | -1.37 |
| Public | 9.58 | 9.39 | 9.32 | 8.96 | 8.76 | 8.6 | 8.54 | 8.58 | -1.0 |
Mutual fund holdings · Oct 2026
440 schemes hold this stock
310 the month before.
- ICICI Prudential Nifty Pharma ETF12.29% of NAV
- Nippon India Nifty Pharma ETF12.28% of NAV
- ICICI Prudential Nifty Pharma Index Fund12.28% of NAV
- PGIM INDIA HEALTHCARE FUND11.08% of NAV
- ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF10.78% of NAV
- DSP Nifty Healthcare Index Fund10.78% of NAV
- Axis NIFTY Healthcare ETF10.78% of NAV
- ICICI Prudential Nifty Healthcare ETF10.78% of NAV
Corporate actions
Recent dividends, bonuses and splits
- 25 Jul 2025 · Final Dividend - Rs. 30
- 02 Aug 2024 · Dividend - Rs. 30
- 11 Aug 2023 · Final Dividend - Rs. 30
- 11 Aug 2022 · Dividend - Rs. 30
- 17 Aug 2021 · Final Dividend - Rs. 20
- 25 Feb 2020 · Interim Dividend - Rs. 16
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.